Status:

TERMINATED

L-Carnitine L-Tartrate in Preventing Peripheral Neuropathy Caused By Chemotherapy in Women With Metastatic Breast Cancer

Lead Sponsor:

HealthPartners Institute

Conditions:

Breast Cancer

Chemotherapeutic Agent Toxicity

Eligibility:

FEMALE

18-120 years

Phase:

PHASE4

Brief Summary

RATIONALE: L-carnitine L-tartrate may prevent peripheral neuropathy caused by chemotherapy. PURPOSE: This randomized clinical trial is studying how well L-carnitine L-tartrate works in preventing per...

Detailed Description

OBJECTIVES: * To evaluate the tolerability and usefulness of the dietary supplement, L-carnitine L-tartrate, in the prevention of chemotherapy-induced peripheral neuropathy in women with metastatic b...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Diagnosis of breast cancer
  • Metastatic disease
  • Scheduled to receive ≥ 1 of the following chemotherapy drugs:
  • Paclitaxel
  • Docetaxel
  • Capecitabine
  • Gemcitabine hydrochloride
  • Concurrent enrollment in the University of Minnesota study "Population Pharmacokinetics and Pharmacogenetics of Gemcitabine in Adult Patients with Solid Tumors" (Human Subjects Code 0508M72989) required
  • Albumin-bound paclitaxel (Abraxane)
  • Doxorubicin hydrochloride
  • PATIENT CHARACTERISTICS:
  • Life expectancy ≥ 6 months
  • Serum creatinine \< 2.0 mg/dL
  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • No history of seizures
  • No uncontrolled hypertension
  • No history of stroke
  • No malabsorption syndrome
  • No cognitive impairment
  • No history of psychiatric disability affecting informed consent or compliance with drug intake
  • Able to take oral medication
  • Able to complete questionnaire(s) alone or with assistance
  • PRIOR CONCURRENT THERAPY:
  • See Disease Characteristics
  • No concurrent warfarin
  • No concurrent radiotherapy

Exclusion

    Key Trial Info

    Start Date :

    January 2 2007

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    May 2 2008

    Estimated Enrollment :

    2 Patients enrolled

    Trial Details

    Trial ID

    NCT00754767

    Start Date

    January 2 2007

    End Date

    May 2 2008

    Last Update

    September 11 2017

    Active Locations (2)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (2 locations)

    1

    Masonic Cancer Center at University of Minnesota

    Minneapolis, Minnesota, United States, 55455

    2

    Park Nicollet Cancer Center

    Saint Louis Park, Minnesota, United States, 55426